Chemical-genetic Screen Identifies Riluzole As an Enhancer of Wnt/β-catenin Signaling in Melanoma

Overview

Journal Chem Biol

Publisher Elsevier

Specialties Biochemistry
Biology
Chemistry

Date 2010 Nov 25

PMID 21095567

Citations 41

Authors

Travis L Biechele

Nathan D Camp

Daniel M Fass

Rima M Kulikauskas

Nick C Robin

Bryan D White

Corinne M Taraska

Erin C Moore

Jeanot Muster

Rakesh Karmacharya

Stephen J Haggarty

Andy J Chien

Randall T Moon

Affiliations

Soon will be listed here.

Abstract

To identify new protein and pharmacological regulators of Wnt/β-catenin signaling, we used a cell-based reporter assay to screen a collection of 1857 human-experienced compounds for their ability to enhance activation of the β-catenin reporter by a low concentration of WNT3A. This identified 44 unique compounds, including the FDA-approved drug riluzole, which is presently in clinical trials for treating melanoma. We found that treating melanoma cells with riluzole in vitro enhances the ability of WNT3A to regulate gene expression, to promote pigmentation, and to decrease cell proliferation. Furthermore riluzole, like WNT3A, decreases metastases in a mouse melanoma model. Interestingly, siRNAs targeting the metabotropic glutamate receptor, GRM1, a reported indirect target of riluzole, enhance β-catenin signaling. The unexpected regulation of β-catenin signaling by both riluzole and GRM1 has implications for the future uses of this drug.

Citing Articles

Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges.

Gajos-Michniewicz A, Czyz M Int J Mol Sci. 2024; 25(23).

PMID: 39684513 PMC: 11641450. DOI: 10.3390/ijms252312804.

Riluzole Reverses Blood-Testis Barrier Loss to Rescue Chemotherapy-Induced Male Infertility by Binding to TRPC.

Huang R, Xia H, Lin W, Wang Z, Li L, Deng J Cells. 2024; 13(23).

PMID: 39682764 PMC: 11640501. DOI: 10.3390/cells13232016.

Unlocking Hope: Therapeutic Advances and Approaches in Modulating the Wnt Pathway for Neurodegenerative Diseases.

Faraji N, Ebadpour N, Abavisani M, Gorji A Mol Neurobiol. 2024; 62(3):3630-3652.

PMID: 39313658 PMC: 11790780. DOI: 10.1007/s12035-024-04462-4.

Blocking the WNT/β-catenin pathway in cancer treatment:pharmacological targets and drug therapeutic potential.

Zhao X, Ma Y, Luo J, Xu K, Tian P, Lu C Heliyon. 2024; 10(16):e35989.

PMID: 39253139 PMC: 11381626. DOI: 10.1016/j.heliyon.2024.e35989.

Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature.

Huang C, Lau T, Smoller B Dermatopathology (Basel). 2024; 11(1):26-51.

PMID: 38247727 PMC: 10801542. DOI: 10.3390/dermatopathology11010005.

References

Moon R, Kohn A, De Ferrari G, Kaykas A . WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701. DOI: 10.1038/nrg1427. View

Maelandsmo G, Holm R, Nesland J, Fodstad O, Florenes V . Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res. 2003; 9(9):3383-8. View

Duprat F, Lesage F, Patel A, Fink M, Romey G, Lazdunski M . The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol. 2000; 57(5):906-12. View

Chien A, Moore E, Lonsdorf A, Kulikauskas R, Rothberg B, Berger A . Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A. 2009; 106(4):1193-8. PMC: 2626610. DOI: 10.1073/pnas.0811902106. View

Seamon K, Padgett W, Daly J . Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A. 1981; 78(6):3363-7. PMC: 319568. DOI: 10.1073/pnas.78.6.3363. View

Taurin S, Sandbo N, Qin Y, Browning D, Dulin N . Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem. 2006; 281(15):9971-6. DOI: 10.1074/jbc.M508778200. View

Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca M . Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008; 105(6):2052-7. PMC: 2538879. DOI: 10.1073/pnas.0708022105. View

Kageshita T, Hamby C, Ishihara T, Matsumoto K, Saida T, Ono T . Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol. 2001; 145(2):210-6. DOI: 10.1046/j.1365-2133.2001.04336.x. View

Rekas A, Alattia J, Nagai T, Miyawaki A, Ikura M . Crystal structure of venus, a yellow fluorescent protein with improved maturation and reduced environmental sensitivity. J Biol Chem. 2002; 277(52):50573-8. DOI: 10.1074/jbc.M209524200. View

10.

Namkoong J, Shin S, Lee H, Marin Y, Wall B, Goydos J . Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res. 2007; 67(5):2298-305. DOI: 10.1158/0008-5472.CAN-06-3665. View

11.

Jho E, Zhang T, Domon C, Joo C, Freund J, Costantini F . Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002; 22(4):1172-83. PMC: 134648. DOI: 10.1128/MCB.22.4.1172-1183.2002. View

12.

Palmer T, Markakis E, Willhoite A, Safar F, Gage F . Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. J Neurosci. 1999; 19(19):8487-97. PMC: 6783019. View

13.

Ring D, Johnson K, Henriksen E, Nuss J, Goff D, Kinnick T . Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003; 52(3):588-95. DOI: 10.2337/diabetes.52.3.588. View

14.

Murakami T, Maki W, Cardones A, Fang H, Kyi A, Nestle F . Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002; 62(24):7328-34. View

15.

Fumagalli E, Bigini P, Barbera S, De Paola M, Mennini T . Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Exp Neurol. 2006; 198(1):114-28. DOI: 10.1016/j.expneurol.2005.11.010. View

16.

Major M, Camp N, Berndt J, Yi X, Goldenberg S, Hubbert C . Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science. 2007; 316(5827):1043-6. DOI: 10.1126/science/1141515. View

17.

Bachmann I, Straume O, Puntervoll H, Kalvenes M, Akslen L . Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res. 2005; 11(24 Pt 1):8606-14. DOI: 10.1158/1078-0432.CCR-05-0011. View

18.

Delmas V, Beermann F, Martinozzi S, Carreira S, Ackermann J, Kumasaka M . Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev. 2007; 21(22):2923-35. PMC: 2049194. DOI: 10.1101/gad.450107. View

19.

Doble A . The pharmacology and mechanism of action of riluzole. Neurology. 1996; 47(6 Suppl 4):S233-41. DOI: 10.1212/wnl.47.6_suppl_4.233s. View

20.

Pollock P, Cohen-Solal K, Sood R, Namkoong J, Martino J, Koganti A . Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet. 2003; 34(1):108-12. DOI: 10.1038/ng1148. View